

Another European patent approval for Episurf Medical

The European Patent Office, EPO, has taken the decision to allow another European patent for Episurf Medical (NASDAQ: EPIS B). The decision was taken at an oral proceeding at the EPO in Munich, Germany. The patent, entitled "System and method for creating a decision support material indicating damage to an anatomical joint" covers Episurf Medical's 3D-based damage marking technology which constitutes a central part of the Episealer® implant system as well as the Epioscopy® joint visualisation system.

"This is a core patent for Episurf's imaging technology, and we are very happy that the oral proceeding went well, and that the EPO decided to allow the patent. Medical imaging is one of the three fundamentals of our technology, together with the individualised implants and surgical instruments. Strong IP is important in all these parts, but imaging is really the basis for the whole technology", comments Katarina Flodström, COO, Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69
Email: p.al.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's µiFidelity® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.

This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16.50 CEST on 16 October 2019.